In the medium-to-long term following kidney transplantation, chronic allograft injury (CAI) induced by immunological or non-immunological factors gradually develops. Approximately 40%-80% of patients present with transplant renal dysfunction characterized by severe proteinuria as the primary clinical manifestation, with or without elevated serum creatinine. As the disease progresses, hypoalbuminemia gradually emerges. During the etiological treatment of CAI, persistent hypoalbuminemia significantly increases the risk of complications, including infections, cardiovascular diseases, calcineurin inhibitor nephrotoxicity, thrombotic diseases, anemia, and frailty. Current clinical practice guidelines maintain relatively strict indications for intravenous albumin supplementation and ultrafiltration/dialysis for volume management. Clinical practice demonstrates that appropriately modifying current management paradigms for hypoalbuminemia—by establishing risk stratification based on multidimensional indicators such as albumin levels, clinical manifestations, and allograft function, and integrating measures such as medication optimization, albumin supplementation, and ultrafiltration/dialysis—to formulate individualized albumin management strategies may help sustain long-term graft and patient survival. Implementing stratified diagnosis and treatment along with multidisciplinary team for kidney transplant recipients with hypoalbuminemia holds promise for reducing complication risks and improving clinical outcomes.